Edmund Kim

Edmund Kim, PhD, is co-founder and COO. He comes from Kite Pharma where was vice president of corporate development. At Kite, Edmund was responsible for cell therapy business development and a member of Kite’s leadership team following its acquisition by Gilead in 2017. Previously, he was senior director of global business development at Mylan NV (now Viatris), and an equity research analyst at J.P. Morgan Securities covering specialty pharmaceutical stocks. Edmund received a PhD in immunology from Weill Cornell Graduate School of Medical Sciences and a BA in molecular biology from Pomona College.